| |
All- Vac group (n = 266)
|
Vac-1 group (n = 91)
|
Vac-2 group (n = 175)
|
Pv
|
|---|
|
Grading
|
Grade 1 VAHL
|
96 (36.1%)
|
40 (44.0%)
|
56 (32.0%)
|
0.05
|
|
Grade 2 VAHL
|
112 (42.1%)
|
40 (44.0%)
|
72 (41.1%)
|
0.66
|
|
Grade 3 VAHL
|
32 (12.0%)
|
7 (7.7%)
|
25 (14.3%)
|
0.12
|
|
Grade 4 VAHL
|
26 (9.8%)
|
4 (4.4%)
|
22 (12.6%)
|
0.03
|
|
Location
|
Axilla-level 1
|
264 (99.2%)
|
90 (98.9%)
|
174 (99.4%)
|
>0.99
|
|
Axilla-level 2
|
100 (37.6%)
|
24 (26.4%)
|
76 (43.4%)
|
0.01
|
|
Axilla-level 3
|
35 (13.2%)
|
7 (7.7%)
|
28 (16.0%)
|
0.06
|
|
Axilla-interpectoral
|
39 (14.7%)
|
5 (5.5%)
|
34 (19.4%)
|
<0.01
|
|
Supraclavicular
|
21 (7.9%)
|
5 (5.5%)
|
16 (9.1%)
|
0.30
|
|
Intensity
|
SUVmax
|
2.63 (1.85–3.82)
|
2.40 (1.74–3.19)
|
2.76 (1.97–4.29)
|
0.01
|
|
Size
|
Enlarged LN
|
37 (13.9%)
|
6 (6.6%)
|
31 (17.7%)
|
0.01
|
| |
Visible injection site
|
99 (37.2%)
|
21 (23.1%)
|
78 (44.6%)
|
<0.01
|
- Categorical variables are reported as frequency and percentage; continuous variables are reported as median and IQR